First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl

Kidney International

Volumn 68, Issue 3, 2005, Pages 1236-1243

  Martin, Kevin J ^a   Jüppner, Harald ^b   Sherrard, Donald J ^b   Goodman, William G ^b   Kaplan, Mark R ^b   Nassar, George ^b   Campbell, Patricia ^b   Curzi, Mario ^b   Charytan, Chaim ^b   McCary, Laura C ^b   Guo, Matthew D ^b   Turner, Stewart A ^b   Bushinsky, David A ^b  

^a SAINT LOUIS UNIVERSITY   (United States)

^b NONE

Author keywords

Bio intact PTH; Cinacalcet HCl; Dialysis; Immunometric PTH assay; Intact PTH; Parathyroid hormone; PTH fragments; Secondary hyperparathyroidism

Indexed keywords

ALKALINE PHOSPHATASE; CALCIMIMETIC AGENT; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; VITAMIN D;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; CALCIUM; DRUG MONITORING; FEMALE; HUMANS; HYPERPARATHYROIDISM; IMMUNOASSAY; LINEAR MODELS; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; TREATMENT OUTCOME; VITAMIN D;

EID: 32644456091     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00517.x     Document Type: Article

References (37)

1. GOODMAN WG, JUPPNER H, SALUSKY IB, et al: Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Kidney Int 63:1-11, 2003
2. GOODMAN WG, RAMIREZ JA, BELIN TR, et al: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160-1166, 1994
3. HERCZ G, PEI Y, GREENWOOD C, et al: Aplastic osteodystrophy without aluminum: The role of "suppressed" parathyroid function. Kidney Int 44:860-866, 1993
4. HO LT, SPRAGUE SM: Renal osteodystrophy in chronic renal failure. Semin Nephrol 22:488-493, 2002
5. SALUSKY IB, KUIZON BD, BELIN TR, et al: Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administration. Kidney Int 54:907-914, 1998
6. ATSUMI K, KUSHIDA K, YAMAZAKI K, et al: Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33:287-293, 1999
7. COCO M, RUSH H: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115-1121, 2000
8. KUIZON BD, GOODMAN WG, JUPPNER H, et al: Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53:205-211, 1998
9. NUSSBAUM SR, ZAHRADNIK RJ, LAVIGNE JR, et al: Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364-1367, 1987
10. BROSSARD JH, CLOUTIER M, ROY L, et al: Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: Importance in the interpretation of PTH values. J Clin Endocrinol Metab 81:3923-3929, 1996
11. LEPAGE R, ROY L, BROSSARD JH, et al: A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 44:805-809, 1998
12. BROSSARD JH, LEPAGE R, CARDINAL H, et al: Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 46:697-703, 2000
13. DAUGAARD H, EGFJORD M, LEWIN E, et al: Metabolism of N-terminal and C-terminal parathyroid hormone fragments by isolated perfused rat kidney and liver. Endocrinology 134:1373-1381, 1994
14. NGUYEN-YAMAMOTO L, ROUSSEAU L, BROSSARD JH, et al: Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays. Eur J Endocrinol 147:123-131, 2002
15. GAO P, SCHEIBEL S, D'AMOUR P, et al: Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16:605-614, 2001
16. JOHN MR, GOODMAN WG, GAO P, et al: A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: Implications for PTH measurements in renal failure. J Clin Endocrinol Metab 84:4287-4290, 1999
17. SALUSKY IB, GOODMAN WG, KUIZON BD, et al: Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 63:1801-1808, 2003
18. NEMETH EF: Calcimimetic and calcilytic drugs: Just for parathyroid cells? Cell Calcium 35:283-289, 2004
19. BLOCK GA, MARTIN KJ, DE FRANCISCO AL, et al: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525, 2004
20. LINDBERG JS, MOE SM, GOODMAN WG, et al: The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 63:248-254, 2003
21. QUARLES LD, SHERRARD DJ, ADLER S, et al: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14:575-583, 2003
22. CARNEVALE V, DIONISI S, NOFRONI I, et al: Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem 50:626-631, 2004
23. INABA M, NAKATSUKA K, IMANISHI Y, et al: Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem 50:385-390, 2004
24. SILVERBERG SJ, GAO P, BROWN I, et al: Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab 88:4725-4730, 2003
25. COEN G, BONUCCI E, BALLANTI P, et al: PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 40:348-354, 2002
26. GODBER IM, PARKER CR, LAWSON N, et al: Comparison of intact and 'whole molecule' parathyroid hormone assays in patients with histologically confirmed post-renal transplant osteodystrophy. Ann Clin Biochem 39:314-317, 2002
27. MIWA N, NITTA K, KIMATA N, et al: An evaluation of 1-84 PTH measurement in relation to bone alkaline phosphatase and bone Gla protein in hemodialysis patients. Nephron Clin Pract 94:c29-32, 2003
28. REICHEL H, ESSER A, ROTH HJ, et al: Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 18:759-768, 2003
29. EKNOYAN G, LEVIN A, LEVIN NW: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1-201, 2003
30. D'AMOUR P, ROUSSEAU L, ROCHELEAU B, et al: Influence of Ca2+ concentration on the clearance and circulating levels of intact and carboxy-terminal iPTH in pentobarbital-anesthetized dogs. J Bone Miner Res 11:1075-1085, 1996
31. HABENER JF, ROSENBLATT M, POTTS JT, JR.: Parathyroid hormone: Biochemical aspects of biosynthesis, secretion, action, and metabolism. Physiol Rev 64:985-1053, 1984
32. MAYER GP, KEATON JA, HURST JG, et al: Effects of plasma calcium concentration on the relative proportion of hormone and carboxyl fragments in parathyroid venous blood. Endocrinology 104:1778-1784, 1979
33. MONIER-FAUGERE MC, GENG Z, MAWAD H, et al: Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 60:1460-1468, 2001
34. SANTAMARIA R, ALMADEN Y, FELSENFELD A, et al: Dynamics of PTH secretion in hemodialysis patients as determined by the intact and whole PTH assays. Kidney Int 64:1867-1873, 2003
35. SLATOPOLSKY E, FINCH J, DENDA M, et al: Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97:2534-2540, 1996
36. CHUDEK J, PIECHA G, KOKOT F, et al: Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients. J Nephrol 16:710-715, 2003
37. GOODMAN WG, HLADIK GA, TURNER SA, et al: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024, 2002